

RNA-sequencing across three matched tissues reveals shared
and tissue-specific gene expression and pathway signatures of COPD

Jarrett D. Morrow¹, Robert P. Chase¹, Margaret M. Parker¹, Kimberly Glass¹, Minseok Seo¹, Miguel Divo², Caroline A. Owen², Peter Castaldi¹, Dawn L. DeMeo^{1,2}, Edwin K. Silverman^{1,2}, Craig P. Hersh^{1,2}

1. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, 02115

2. Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, 02115

Table S1. Demographics of study subjects

| Demographics | COPD cases n=6 | Controls n=11 | Never-smoker controls n=4 |
|--|---------------------------|--------------------------|--|
| Tissue samples: | | | |
| large airway | 6 | 11 | 4 |
| alveolar macrophage | 6 | 11 | 4 |
| peripheral blood | 6 | 11 | 4 |
| Age at enrollment (years) | 63.0 (± 3.4) | 64.2 (± 6.4) | 56.1 (± 9.4) |
| Gender (female / male) | 3 / 3 | 8 / 3 | 0 / 4 |
| Race: | | | |
| African American | 0 | 6 | 0 |
| White | 6 | 5 | 4 |
| Cigarette smoking status: | | | |
| Never Smokers | 0 | 0 | 4 |
| Former Smokers | 2 | 8 | 0 |
| Current Smokers | 4 | 3 | 0 |
| Smoking History (pack-years) | 36.3 (± 10.1) | 26.9 (± 15.0) | NA |
| FEV1 % predicted | 78.7 (± 19.6) | 107.0 (± 13.5) | 98.2 (±4.9) |
| FEV1/FVC | 0.59 (± 0.1) | 0.79 (± 0.05) | 0.8 (±0.03) |
| Body Mass Index | 24.6 (±1.4) | 31.4 (±6.5) | 28.7 (±3.6) |
| % emphysema (6 cases, 10 controls, 4 never-smokers) | 7.9% (±7.1%) | 1.9% (±2.3%) | 0.7 (±0.4) |
| 15th percentile of lung density histogram (6 cases, 10 controls, 4 never-smokers) | -929.5 (±23.7) | -910.2 (±10.1) | -904 (±17.8) |
| Adjusted lung density, sponge model adjustment (6 cases, 10 controls, 1 never-smoker) | 66.3 (±16.7) | 84.6±13.1 | 62.4 (±NA) |
| SRWA-Pi10 (6 cases, 9 controls, 3 never-smokers) | 2.24 (±0.41) | 1.79 (±0.45) | 2.17 (±0.62) |
| Airway Wall Thickness, segmental bronchi (6 cases, 9 controls, 3 never-smokers) | 1.12 (±0.19) | 0.88 (±0.15) | 0.96 (±0.22) |
| Wall Area Percent, segmental bronchi (6 cases, 9 controls, 3 never-smokers) | 51.8 (±6.2) | 42.6 (±7.4) | 48.2 (±9.9) |
| <p>Abbreviations: FEV1=forced expiratory volume in 1 sec; FVC= forced vital capacity; CT=computed tomography; SRWA-Pi10=square root wall area of a hypothetical airway with 10mm internal perimeter; Hu=Hounsfield unit</p> <p>statistical tests: Fisher's Exact Test for categorical variables and Welch Two Sample t-test for continuous variables</p> | | | |

Table S2. Number of genes with DESeq2 results overlapping across the four combined phenotype categories and three tissues (labels: phenotype category - tissue)

| | Emph blood | Lung function blood | Smoking blood | Airway blood | Emph bronch | Lung function bronch | Smoking bronch | Airway bronch | Emph macro | Lung function macro | Smoking macro | Airway macro |
|---------------------------------------|-----------------------|------------------------------------|--------------------------|-------------------------|------------------------|-------------------------------------|---------------------------|--------------------------|-----------------------|------------------------------------|--------------------------|-------------------------|
| Emphysema - blood | 20078 | | | | | | | | | | | |
| Lung function - blood | 14691 | 16215 | | | | | | | | | | |
| Smoking - blood | 13220 | 12491 | 13890 | | | | | | | | | |
| Airway - blood | 15009 | 12540 | 12193 | 15045 | | | | | | | | |
| Emphysema - bronchial | 16579 | 16215 | 13129 | 13336 | 20140 | | | | | | | |
| Lung function - bronchial | 16804 | 14832 | 13890 | 13959 | 16779 | 19620 | | | | | | |
| Smoking - bronchial | 20078 | 15433 | 13579 | 15045 | 18268 | 18119 | 23819 | | | | | |
| Airway - bronchial | 16579 | 16215 | 13129 | 13336 | 20140 | 16779 | 18268 | 20140 | | | | |
| Emphysema - macrophage | 16804 | 14832 | 13890 | 13959 | 16779 | 19620 | 18119 | 16779 | 19620 | | | |
| Lung function - macrophage | 20064 | 15409 | 13559 | 15036 | 18200 | 18055 | 23493 | 18200 | 18055 | 23580 | | |
| Smoking - macrophage | 16532 | 16174 | 13094 | 13295 | 19896 | 16750 | 18229 | 19896 | 16750 | 18159 | 20076 | |
| Airway - macrophage | 16773 | 14786 | 13821 | 13942 | 16750 | 19342 | 18102 | 16750 | 19342 | 18041 | 16722 | 19646 |

Table S3. Number of significant results from the DESeq2 analysis for each model and tissue (phenotype variables are color-coded to match the row labels in Figure 5; blue = lung function, red = smoking; green = emphysema, brown = airway)

| Phenotype variable | Phenotype description | Tissue | Number of significant results (q < 0.1) |
|--------------------|---|--------|---|
| COPD | COPD case-control | bronch | 19 |
| COPD | COPD case-control | blood | 13 |
| COPD | COPD case-control | macro | 99 |
| FEV1 _{pp} | forced expiratory volume in 1 second - % predicted | bronch | 23 |
| FEV1 _{pp} | forced expiratory volume in 1 second - % predicted | blood | 0 |
| FEV1 _{pp} | forced expiratory volume in 1 second - % predicted | macro | 0 |
| FEV1/FVC | Ratio of forced expiratory volume in 1 sec to forced vital capacity | bronch | 3 |
| FEV1/FVC | Ratio of forced expiratory volume in 1 sec to forced vital capacity | blood | 0 |
| FEV1/FVC | Ratio of forced expiratory volume in 1 sec to forced vital capacity | macro | 7 |
| Pack-years | Pack-years of smoking | bronch | 18 |
| Pack-years | Pack-years of smoking | blood | 7 |
| Pack-years | Pack-years of smoking | macro | 4 |
| Smoking | 0 non-smoker, 1 former smoker, 2 current smoker | bronch | 317 |
| Smoking | 0 non-smoker, 1 former smoker, 2 current smoker | blood | 1 |
| Smoking | 0 non-smoker, 1 former smoker, 2 current smoker | macro | 1886 |
| %Emph | percent emphysema | bronch | 16 |
| %Emph | percent emphysema | blood | 1430 |
| %Emph | percent emphysema | macro | 4 |
| Perc15 | 15th percentile of lung density histogram + 1000 Hu | bronch | 0 |
| Perc15 | 15th percentile of lung density histogram + 1000 Hu | blood | 1692 |
| Perc15 | 15th percentile of lung density histogram + 1000 Hu | macro | 2 |
| Adjusted density | adjusted lung density, sponge model adjustment | bronch | 5 |
| Adjusted density | adjusted lung density, sponge model adjustment | blood | 263 |
| Adjusted density | adjusted lung density, sponge model adjustment | macro | 0 |
| Pi10 = SRWA-Pi10 | square root wall area of a hypothetical airway with 10mm internal perimeter | bronch | 62 |
| Pi10 = SRWA-Pi10 | square root wall area of a hypothetical airway with 10mm internal perimeter | blood | 1 |
| Pi10 = SRWA-Pi10 | square root wall area of a hypothetical airway with 10mm internal perimeter | macro | 12 |
| AWT | airway wall thickness, segmental bronchi | bronch | 257 |
| AWT | airway wall thickness, segmental bronchi | blood | 0 |
| AWT | airway wall thickness, segmental bronchi | macro | 388 |
| WallAreaPct | wall area percent, segmental bronchi | bronch | 159 |
| WallAreaPct | wall area percent, segmental bronchi | blood | 0 |
| WallAreaPct | wall area percent, segmental bronchi | macro | 156 |

Table S4. DESeq2 differential expression results for 11 phenotypes (from Table S1 in Supplemental Tables) in bronchial epithelium (see Table_S4.xls)

Table S5. DESeq2 differential expression results for 11 phenotypes (from Table S1 in Supplemental Tables) in alveolar macrophages (see Table_S5.xls)

Table S6. DESeq2 differential expression results for 11 phenotypes (from Table S1 in Supplemental Tables) in peripheral blood (see Table_S6.xls)

Table S7. Gene symbols at the intersection of results across tissue (results label: phenotype category_tissue)

| Overlapping differential gene expression results | Intersecting gene symbols |
|---|--|
| emphysema_blood & emphysema_bronch | <i>FCN1</i> |
| emphysema_blood & emphysema_macro | <i>NBPF3</i> |
| smoking_blood & smoking_macro | <i>IFIT3, IFIT2, RSAD2, FZD6</i> |
| smoking_bronch & smoking_macro | <i>CCDC81, VGLL3, CYP1B1, CCL24, KIF21A, CYP1B1-AS1, UCHL1, CRISP3, CNTN5, DTNA, LTBP1, SLIT2, PROM1, AHRR, NECTIN3, SCGB1A1, PID1, LTF, AC112198.2, UPK1B, CNTD1, PROK2, SERTAD4, PCDH17, SAA1, ABCA13, CCL20, LINC02300, MAK, SYNM, SPAG1, C1orf158, C1orf116, CCDC181, MNS1, BIRC3, MAP3K19, TSPAN2, TMC5, OSBPL6, LUCAT1, ZNF860, SERPINB10, SOD2, CLDN16, TMPRSS4, SERPINB4, FBXW10, MYLK3, ZNF204P, IL5RA, FAM3B, CERKL, FAM216B, GBP1, DPYSL3, AKR1C2</i> |
| lungfunc_blood & lungfunc_macro | <i>LINC02384, HLA-V</i> |
| airway_bronch & airway_macro | <i>MIR3142HG, ABLIM1, SNORA49, SLC7A11, CYP3A5, PRSS12, ABCA13, C1orf87, AGR2, SCGB1A1, MPDZ, SCARNA13, CKAP4, CLEC4F, TRBC1, SPOCK2, SERPINB5</i> |

Table S8. Results from cross-tissue gene and pathway enrichment for results from each phenotype category

| | Genes | | | Pathways | | |
|--|-----------------------|----------------------------|-----------------------|-----------------------|----------------------------|-----------------------|
| | Epithelium-- Blood | Epithelium-- Macrophage | Blood-- Macrophage | Epithelium-- Blood | Epithelium-- Macrophage | Blood-- Macrophage |
| Lung Function | 1 | 1 | 0.003 | 0.009 | < 0.0001 | 1 |
| Emphysema | 0.7 | 1 | 0.4 | < 0.0001 | < 0.0001 | 0.4 |
| Airway disease | 1 | 0.002 | 1 | 0.006 | < 0.0001 | 1 |
| Smoking | 1 | < 0.0001 | 0.001 | < 0.0001 | < 0.0001 | 0.003 |
| p-values from hypergeometric tests of enrichment | | | | | | |

| | |
|----------|---|
| REACTOME | G1_S_TRANSITION, |
| KEGG | OXIDATIVE_PHOSPHORYLATION, |
| REACTOME | PEPTIDE_CHAIN_ELONGATION, |
| REACTOME | CELL_CYCLE_CHECKPOINTS, REACTOME_METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES, |
| KEGG | PARKINSONS_DISEASE, |
| REACTOME | RESPIRATORY_ELECTRON_TRANSPORT_ATP_SYNTHESIS_BY_CHEMIOSMOTIC_COUPLING_AND_HEAT_PRODUCED_BY_UNCOUPLING_PROTEINS, |
| REACTOME | UNFOLDED_PROTEIN_RESPONSE, |
| REACTOME | S_PHASE, |
| REACTOME | M_G1_TRANSITION, |
| REACTOME | SYNTHESIS_OF_DNA, |
| REACTOME | HIV_INFECTION, |
| REACTOME | SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR, |
| REACTOME | ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIF5_AND_SU_BSEQUENT_BINDING_TO_43S, |
| REACTOME | REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THAT_BIND_AU_RICH_ELEMENTS, |
| REACTOME | DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR, |
| REACTOME | RESPIRATORY_ELECTRON_TRANSPORT, |
| REACTOME | ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION, |
| REACTOME | MITOTIC_PROMETAPHASE, |
| REACTOME | ASSEMBLY_OF_THE_PRE_REPLICATIVE_COMPLEX, |
| REACTOME | ANTIGEN_PROCESSING_CROSS_PRESENTATION, |
| REACTOME | FORMATION_OF_THE_TERNARY_COMPLEX_AND_SUBSEQUENTLY_THE_43S_COMPLEX, |
| REACTOME | P53_DEPENDENT_G1_DNA_DAMAGE_RESPONSE, |
| REACTOME | ORC1_REMOVAL_FROM_CHROMATIN, |
| REACTOME | DESTABILIZATION_OF_MRNA_BY_AUF1_HNRNP_D0, |
| REACTOME | ER_PHAGOSOME_PATHWAY, |
| REACTOME | APC_C_CDC20_MEDIATED_DEGRADATION_OF_MITOTIC_PROTEINS, |
| REACTOME | REGULATION_OF_MITOTIC_CELL_CYCLE, |
| REACTOME | SIGNALING_BY_WNT, |
| REACTOME | APC_C_CDHI_MEDIATED_DEGRADATION_OF_CDC20_AND_OTHER_APC_C_CDHI_TARGETED_PROTEINS_IN_LATE_MITOSIS_EARLY_G1, |
| REACTOME | P53_INDEPENDENT_G1_S_DNA_DAMAGE_CHECKPOINT, |
| REACTOME | CDT1_ASSOCIATION_WITH_THE_CDC6_ORC_ORIGIN_COMPLEX, REACTOME_HIV_LIFE_CYCLE, |
| REACTOME | CYCLIN_E_ASSOCIATED_EVENTS_DURING_G1_S_TRANSITION, |
| REACTOME | CDK_MEDIATED_PHOSPHORYLATION_AND_REMOVAL_OF_CDC6, |
| REACTOME | PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA, |
| REACTOME | CROSS_PRESENTATION_OF_SOLUBLE_EXOGENOUS_ANTIGENS_ENDOSOMES, |
| REACTOME | AUTODEGRADATION_OF_THE_E3_UBIQUITIN_LIGASE_COPI, |
| KEGG | UBIQUITIN_MEDIATED_PROTEOLYSIS, REACTOME_SCFSKP2_MEDIATED_DEGRADATION_OF_P27_P21, |
| REACTOME | REGULATION_OF_ORNITHINE_DECARBOXYLASE_ODC, |
| REACTOME | SCF_BETA_TRCP_MEDIATED_DEGRADATION_OF_EM11, |
| REACTOME | LATE_PHASE_OF_HIV_LIFE_CYCLE, |
| REACTOME | MRNA_SPLICING, |
| REACTOME | MRNA_PROCESSING, |
| REACTOME | AUTODEGRADATION_OF_CDHI_BY_CDHI_APC_C, |
| REACTOME | VIF_MEDIATED_DEGRADATION_OF_APOBEC3G, |
| REACTOME | G2_M_CHECKPOINTS, |
| REACTOME | E2F_MEDIATED_REGULATION_OF_DNA_REPLICATION, |
| KEGG | FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS, |
| KEGG | SPLICEOSOME, |
| REACTOME | PROTEIN_FOLDING, |
| REACTOME | DNA_REPAIR, |
| REACTOME | RNA_POL_II_TRANSCRIPTION, |
| REACTOME | MITOCHONDRIAL_PROTEIN_IMPORT, |
| REACTOME | MRNA_SPLICING_MINOR_PATHWAY, |
| REACTOME | PREFOLDIN_MEDIATED_TRANSFER_OF_SUBSTRATE_TO_CCT_TRIC, |
| REACTOME | TRNA_AMINOACYLATION |

Table S10. Overlapping genes from significant (q-value < 0.1) DESeq2 differential gene expression results and the findings from previous studies (rows labeled by: phenotype variable - tissue)

| | Lung DGE up (1) | Lung DGE down (1) | B cell (1) | Lung emph up (1) | Lung emph down (1) | Lung EWAS (2) | GWAS (3) |
|---------------------------|--|----------------------------------|--|---|-------------------------------|---|--|
| COPD - bronch | | | CD28 | | | | ADAMTSL3 |
| COPD - blood | | | | | | PTPRE | IER3 |
| COPD - macro | FCRL2, FCGR2B | PI4K2B, EIF3F | STAP1, FCRL2 | FCGR2B | PI4K2B, EIF3F, CD101 | KALRN, ACSM1 | |
| FEV1pp - bronch | | EXOC8 | | | EXOC8 | | |
| Pack-years - macro | PLA2G7 | | | | | | |
| Smoking - bronch | SV2B | CIT, RASGEF1B | | | FXR1, FTH1 | THSD7A, DTNA, SLC7A8, BOK, OSBPL6, FERMT1 | TIMP3, PID1, AZGP1, CNGB1 |
| Smoking - macro | POU2AF1, PLA2G7, FCGR2B, CD24, FCRL2, SERPINE2 | CLEC2D, MYO5B, KRT8, LY75, FBXO5 | POU2AF1, FCRL2, TLR10, CD28, AIM2, LAX1, COCH, HLA-DOB, FAM46C | C1S, CD8A, SYTL2, FCGR2B, FAM20C, SULF1, SAMD3, CALD1, MAP1A, CACNA1C, GZMK, LIMA1, EMILIN1, OSBPL10, PYHIN1, CD5, PLTP | XAF1, ACAD8, SCD, CD101, LY75 | DIXDC1, DNAH6, TMEM163, LRIG1, RPS6KA2, OSBPL6, PLCB4, CCDC80, CNN3, FOXP2, SHANK2, IL7, CACHD1, TEAD1, FILIP1, PLXNB1, FARP1, DTNA, NUP210L, RAB36, ALDH2, RNASE1, C5orf49, THSD4, MSI2, ERN2, NR3C2, TMEM212, SPIDR, PTPN6, TEK2, IRF4, RASGRP1, TGFBI, AGBL4, KALRN, ZNF608, TEX14, VILL, SORT1, CCDC68, DUSP2, RUNX2, LHFPL2, SMAD3 | TNS1, C1orf87, PPP1R3B, MECOM, ITGA2, CHRNA5, SLC27A2, HYKK, DYDC2, PID1, ID4, CALHM6, THSD4, DSP, RBMS3, PARVA, GSDMB, RARB, FAM49A |
| %Emph - blood | ZNF101, | METTL18, | TMEM156, | FPGT | MS4A7, PSMC6, | CLN6, ZNF136, | CCDC91, |

| | | | | | | | |
|--------------------------------------|---|--|--|--|--|---|--|
| | FPGT, EEF1B2, MS4A1, MTHFD2L | DNTTIP2, HSP90AA1, ZCCHC10, HSPA13, PSMC6, CCDC82, XRCC4, PI4K2B, CBWD1, FBXO5, SOCS4, HMGB1, ADH5, SREK1IP1, TPRKB, DNAJB14, NUDT21, SNRPG, VEZT, HNRNPA1, C11orf58, TAF9, RASGEF1B | FAM69A, STAP1, AIM2, BTLA, COCH, MS4A1, EAF2 | | PI4K2B, LIN7C, NPM1, SOCS4, CCDC91, HMGB1, COMMD8, EIF4E, FXR1, DNAJB14, NUDT21, ZNF354B, NCF1, PFKFB4, HNRNPA3, SRSF3, HNRNPA1, ZBTB8OS, C11orf58, TAF9, ZNRF2, TAF1D | ZNF608, PLEKHO2, TP53RK, SLC43A2, ZBTB25, ALOX5, KCNQ1, PSD4, IQSEC1, GNAI2, RBM12B | DRAM2, ITPK1, IER3, PADI2, HIKESHI, PPA2, MRPS35, PSMA4, HSPA4, PPM1K, SSR1, ATG7, VTA1, ADAM19 |
| Perc15 - blood | EEF1B2, MS4A1, MTHFD2L, ZNF101 | ZCCHC10, PSMC6, SNRPG, PI4K2B, HSPA13, CBWD1, METTL18, HSP90AA1, HMGB1, SREK1IP1, XRCC4, VEGFA, TAGLN2, TPRKB, NUDT21, ADH5, SOCS4, DNAJB14, C11orf58, DNTTIP2, TAF9, CCDC82, RASGEF1B, MRPL47, FBXO5, RAC1, NIPSNAP3A, C6orf62, PEX3 | BTLA, STAP1, FAM69A, TMEM156, MS4A1, EAF2, RAB30 | | CCDC91, PSMC6, COMMD8, NCF1, MS4A7, PI4K2B, HMGB1, PFKFB4, PDE4DIP, LIN7C, EIF4E, NUDT21, SOCS4, DNAJB14, C11orf58, TAF9, ZNRF2, CLOCK, HNRNPA3, PDCD10, NPM1, XAF1, SRSF3, ZBTB8OS, MLX, ZNF354B, TAF1D, RAC1, C6orf62, FXR1, PEX3 | CLN6, ALOX5, PLEKHO2, PSD4, SLC43A2, KCNQ1, ARID3A, FCGRT, LSP1, GNAI2, KIF13A, IL6R, ZBTB25, CTDSP1, PTPRE, GLT1D1, SBNO2, IQSEC1, ATP6V1B2, HACE1, SVIL, VAV1, KSR1, TRAF5, TP53RK | CCDC91, ITPK1, DRAM2, PSMA4, PPA2, HIKESHI, RRP15, RIN3, PPM1K, MRPS35, VTA1 |
| Adjusted_density - bronch | | | | | | DHRS7 | |

| | | | | | | | |
|---------------------------------|-----------------------------|--|-------------|----------------------------|-----------------------------|---|-------------------------------------|
| Adjusted_density - blood | ZNF101 | ZCCHC10, HSP90AA1, TPRKB, DNTTIP2, PSMC6, HSPA13 | STAP1 | | MS4A7, PSMC6, COMMD8, LIN7C | | |
| Pi10 - bronch | | | | | | | FAM49A |
| AWT - bronch | | S100A10 | | KLF12 | | FUT3, THSD7A, BOK, ZNF608, FRMD4A | PTHLH, C1orf87 |
| AWT - macro | FCGR2B, CD24, PLA2G7, FCRL2 | KRT8, MYO5B | FCRL2, CD28 | FCGR2B, CD8A, SAMD3, SYTL2 | | RASGRP1, ELF5, PLCB4, IL7, CACHD1, HOXB4, KALRN, DNAH6, HOXB3, IL6R | PID1, MECOM, CYFIP2, C1orf87, ITGA2 |
| WallAreaPct - bronch | | | | ANXA6, SULF1 | | UGCG, FRMD4A | PTHLH |
| WallAreaPct - macro | FCRL2, EEF1B2 | SNRPG | FCRL2 | | NPM1 | RASGRP1, KLHL29, AMOTL1 | CYFIP2 |

DGE = differential gene expression; EWAS = epigenome-wide association study; GWAS = genome-wide association study

COPD = case-control status; FEV1=forced expiratory volume in 1 sec

pack-years = pack-years of smoking; smoking = 0 non-smoker, 1 former smoker, 2 current smoker

pctEmph = % emphysema; perc15 = 15th percentile of lung density histogram + 1000 Hu

adj_density = adjusted lung density, sponge model adjustment

Pi10 = SRWA-Pi10 = square root wall area of a hypothetical airway with 10mm internal perimeter

AWT = airway wall thickness; WallAreaPct = wall area percent

Table S11. CMap connectivity A549 cell-line findings for bronchial epithelium genes up-regulated and down-regulated in airway disease (no Connectivity Map classes achieved an absolute score greater than 95)

| Score | Compound Name | Description |
|--------|---|--|
| -99.3 | lomerizine | Calcium channel blocker |
| -99.24 | radicicol | HSP inhibitor |
| -99.22 | CAY-10578 | Casein kinase inhibitor |
| -99.04 | flavokavain-b | Antineoplastic |
| -98.95 | n-(3-acetamidophenyl)-3-chlorobenzamide | Glutamate receptor antagonist |
| -98.92 | dehydroisoandrosterone | GABA receptor modulator |
| -98.78 | methocarbamol | Muscle relaxant |
| -98.19 | aminolevulinic-acid | Oxidizing agent |
| -98.1 | apicidin | HDAC inhibitor |
| -98.01 | icilin | TRPV agonist |
| -97.75 | alprazolam | Benzodiazepine receptor agonist |
| -97.13 | nadolol | Adrenergic receptor antagonist |
| -96.55 | digitoxigenin | ATPase inhibitor |
| -96.42 | BIIB021 | HSP inhibitor |
| -96.35 | MLN-4924 | Nedd activating enzyme inhibitor |
| -96.19 | oxyphenonium | Cholinergic receptor antagonist |
| -96.08 | fluocinolone | Glucocorticoid receptor agonist |
| -95.62 | tolcapone | Catechol O methyltransferase inhibitor |
| -95.27 | nilutamide | Androgen receptor antagonist |
| -95.12 | westcort | Glucocorticoid receptor agonist |

Table S12. CMap connectivity HCC515 cell-line findings for bronchial epithelium genes up-regulated and down-regulated in airway disease (Connectivity Map classes with absolute score greater than 95 shown at bottom)

| Score | Compound Name | Description |
|--------|---------------------------------|---|
| -99.69 | ephedrine | Adrenergic receptor agonist |
| -99.49 | cycloserine | Bacterial cell wall synthesis inhibitor |
| -98.83 | norethisterone | Progesterone receptor agonist |
| -98.69 | rimantadine | Antiviral |
| -98.54 | amcinonide | Glucocorticoid receptor agonist |
| -98.54 | fludrocortisone | Glucocorticoid receptor agonist |
| -98.53 | dihydrodeoxygedunin | Growth factor receptor activator |
| -98.44 | emetine | Protein synthesis inhibitor |
| -98.38 | 17-hydroxyprogesterone-caproate | progesterone receptor agonist |
| -98.33 | AT-7519 | CDK inhibitor |
| -98.31 | R-59022 | Diacylglycerol kinase inhibitor |
| -98.26 | SB-590885 | RAF inhibitor |
| -98.14 | narciclasine | Cofilin signaling pathway activator |
| -97.87 | gefitinib | EGFR inhibitor |
| -97.81 | homoharringtonine | Protein synthesis inhibitor |
| -97.66 | protopine | Histamine receptor antagonist |
| -97.57 | desoximetasone | Glucocorticoid receptor agonist |
| -97.36 | thalidomide | TNF production inhibitor |
| -97.23 | QL-X-138 | MTOR inhibitor |
| -97.15 | triamcinolone | Glucocorticoid receptor agonist |
| -97.13 | flunisolide | Cytochrome P450 inhibitor |
| -96.87 | AS-703026 | MEK inhibitor |
| -96.69 | budesonide | Glucocorticoid receptor agonist |
| -96.67 | cefixime | Bacterial cell wall synthesis inhibitor |
| -96.63 | fluciconide | Glucocorticoid receptor agonist |
| -96.57 | hydrocortisone | Glucocorticoid receptor agonist |
| -96.44 | halcinonide | Glucocorticoid receptor agonist |
| -96.39 | NU-7441 | DNA dependent protein kinase inhibitor |
| -96.18 | 5'-guanidinonaltrindole | Opioid receptor antagonist |
| -95.95 | RHO-kinase-inhibitor-II | Rho associated kinase inhibitor |
| -95.91 | etilefrine | Adrenergic receptor agonist |
| -95.75 | XMD-885 | Leucine rich repeat kinase inhibitor |
| -95.69 | fluticasone | Glucocorticoid receptor agonist |

| | | |
|-------------------------------|---------------|---|
| -95.63 | teicoplanin | Bacterial cell wall synthesis inhibitor |
| -95.5 | alclometasone | Glucocorticoid receptor agonist |
| -95.48 | GW-583340 | EGFR inhibitor |
| -95.41 | vinpocetine | Phosphodiesterase inhibitor |
| -95.33 | cephaeline | Protein synthesis inhibitor |
| -95.19 | MK-212 | Serotonin receptor agonist |
| Connectivity Map Class | | |
| -96.8 | NA | Rho associated kinase inhibitor |
| -95.75 | NA | Protein synthesis inhibitor |
| -95.66 | NA | Homeobox Gene GOF |
| -95.22 | NA | Glucocorticoid receptor agonist |

References

1. Morrow JD, Zhou X, Lao T, Jiang Z, DeMeo DL, Cho MH, Qiu W, Cloonan S, Pinto-Plata V, Celli B, Marchetti N, Criner GJ, Bueno R, Washko GR, Glass K, Quackenbush J, Choi AMK, Silverman EK, Hersh CP. Functional interactors of three genome-wide association study genes are differentially expressed in severe chronic obstructive pulmonary disease lung tissue. *Scientific Reports* 2017;7:44232.
2. Morrow JD, Cho MH, Hersh CP, Pinto-Plata V, Celli B, Marchetti N, Criner G, Bueno R, Washko G, Glass K, Choi AMK, Quackenbush J, Silverman EK, DeMeo DL. DNA methylation profiling in human lung tissue identifies genes associated with COPD. *Epigenetics* 2016;11:730–739.
3. Sakornsakolpat P, Prokopenko D, Lamontagne M, Reeve NF, Guyatt AL, Jackson VE, Shrine N, Qiao D, Bartz TM, Kim DK, Lee MK, Latourelle JC, Li X, Morrow JD, Obeidat M, Wyss AB, Zhou X, Bakke P, Barr RG, Beaty TH, Belinsky SA, Brusselle GG, Crapo JD, Jong K de, DeMeo DL, Fingerlin TE, Gharib SA, Gulsvik A, Hall IP, *et al.* Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. *Nature Genetics* 2019;51:494–505.